Department of Pharmacy, Chengdu Military General Hospital, Chengdu, China.
Pharmacology. 2012;90(3-4):177-82. doi: 10.1159/000342128. Epub 2012 Aug 29.
In this study, we combined the dipeptidyl peptidase-4 inhibitor sitagliptin with the antidiabetic drug mangiferin to examine the effects on active glucagon-like peptide-1 (GLP-1) and glucose tolerance in streptozotocin-diabetic rats. Active GLP-1 levels were measured by an ELISA kit. Insulin levels were measured by an RIA kit. Islet morphology was determined by double immunolabeling. Sitagliptin (1 mg/kg) or mangiferin (20 mg/kg) single treatment improved glucose tolerance during an oral glucose tolerance test. In addition, the combination therapy improved glucose tolerance with an increase in plasma insulin level and active GLP-1 levels. Islets from combination-treated diabetic rats had markedly increased β-cell/islet area ratio compared with islets from the diabetic or single-treatment rats. In conclusion, these results indicate that the combination therapy is useful as a therapeutic agent for impaired glucose tolerance and type 2 diabetes.
在这项研究中，我们将二肽基肽酶-4 抑制剂西他列汀与抗糖尿病药物芒果苷联合使用，以研究其对链脲佐菌素糖尿病大鼠活性胰高血糖素样肽-1（GLP-1）和葡萄糖耐量的影响。活性 GLP-1 水平通过 ELISA 试剂盒进行测量。胰岛素水平通过 RIA 试剂盒进行测量。胰岛形态通过双重免疫标记法确定。西他列汀（1 mg/kg）或芒果苷（20 mg/kg）单药治疗可改善口服葡萄糖耐量试验期间的葡萄糖耐量。此外，联合治疗可改善葡萄糖耐量，增加血浆胰岛素水平和活性 GLP-1 水平。与糖尿病大鼠或单一治疗大鼠的胰岛相比，联合治疗糖尿病大鼠的胰岛β细胞/胰岛面积比明显增加。总之，这些结果表明，联合治疗作为治疗葡萄糖耐量受损和 2 型糖尿病的药物是有用的。
